. . "1"^^ . "Bevacizumab (Avastin) in treatment of refractory diabetic macular edema"@en . "Sborn\u00EDk abstrakt IX. kongresu \u010CVRS, Pr\u016Fhonice" . . "Bevacizumab (Avastin) v l\u00E9\u010Db\u011B refraktern\u00EDho diabetick\u00E9ho makul\u00E1rn\u00EDho ed\u00E9mu" . . "\u010Cesk\u00E1 vitreoretin\u00E1ln\u00ED spole\u010Dnost" . "[2D87822ED008]" . "Diabetick\u00FD makul\u00E1rn\u00ED ed\u00E9m (DME) je z\u00E1va\u017Enou komplikac\u00ED diabetick\u00E9 retinopatie (DR) a zp\u016Fsobuje pokles zrakov\u00E9 ostrosti u posti\u017Een\u00FDch pacient\u016F. Vyskytuje se p\u0159edev\u0161\u00EDm u diabetik\u016F 2. typu. Pro diabetiky 1. typu jsou typick\u00E9 p\u0159edev\u0161\u00EDm proliferativn\u00ED zm\u011Bny charakteru trak\u010Dn\u00ED amoce a sklivcov\u00E9ho krv\u00E1cen\u00ED. DME se vyskytuje v jak\u00E9mkoliv st\u00E1diu DR, tj. u proliferativn\u00ED i neproliferativn\u00ED formy. Je zp\u016Fsobem p\u0159edev\u0161\u00EDm zv\u00FD\u0161enou c\u00E9vn\u00ED permeabilitou kapil\u00E1rn\u00ED s\u00EDt\u011B v makul\u00E1rn\u00ED oblasti. Vede k depozici lipoprotein\u016F a ztlu\u0161t\u011Bn\u00ED s\u00EDtnice v centr\u00E1ln\u00ED oblasti. V inici\u00E1ln\u00EDch f\u00E1z\u00EDch DME je pokles zrakov\u00E9 ostrosti reverzibiln\u00ED. Dlouho trvaj\u00EDc\u00ED ed\u00E9m vede k ireverzibiln\u00ED ztr\u00E1t\u011B zrakov\u00E9 ostrosti. Bevacizumab (Avastin Genetech, Roche) je protil\u00E1tka proti VEGF A molekule. Jedn\u00E1 se o kompletn\u00ED molekulu humanizovan\u00E9 my\u0161\u00ED protil\u00E1tky. Tato molekula byla vyrobena pro pot\u0159eby onkologie k syst\u00E9mov\u00E9 aplikaci. Proveden\u00E9 studie prok\u00E1zaly jej\u00ED efekt ve smyslu redukce makul\u00E1rn\u00EDho ed\u00E9mu a zlep\u0161en\u00ED zrakov\u00E9 ostrosti u pacient\u016F s DME." . "1"^^ . . . . . "Diabetick\u00FD makul\u00E1rn\u00ED ed\u00E9m (DME) je z\u00E1va\u017Enou komplikac\u00ED diabetick\u00E9 retinopatie (DR) a zp\u016Fsobuje pokles zrakov\u00E9 ostrosti u posti\u017Een\u00FDch pacient\u016F. Vyskytuje se p\u0159edev\u0161\u00EDm u diabetik\u016F 2. typu. Pro diabetiky 1. typu jsou typick\u00E9 p\u0159edev\u0161\u00EDm proliferativn\u00ED zm\u011Bny charakteru trak\u010Dn\u00ED amoce a sklivcov\u00E9ho krv\u00E1cen\u00ED. DME se vyskytuje v jak\u00E9mkoliv st\u00E1diu DR, tj. u proliferativn\u00ED i neproliferativn\u00ED formy. Je zp\u016Fsobem p\u0159edev\u0161\u00EDm zv\u00FD\u0161enou c\u00E9vn\u00ED permeabilitou kapil\u00E1rn\u00ED s\u00EDt\u011B v makul\u00E1rn\u00ED oblasti. Vede k depozici lipoprotein\u016F a ztlu\u0161t\u011Bn\u00ED s\u00EDtnice v centr\u00E1ln\u00ED oblasti. V inici\u00E1ln\u00EDch f\u00E1z\u00EDch DME je pokles zrakov\u00E9 ostrosti reverzibiln\u00ED. Dlouho trvaj\u00EDc\u00ED ed\u00E9m vede k ireverzibiln\u00ED ztr\u00E1t\u011B zrakov\u00E9 ostrosti. Bevacizumab (Avastin Genetech, Roche) je protil\u00E1tka proti VEGF A molekule. Jedn\u00E1 se o kompletn\u00ED molekulu humanizovan\u00E9 my\u0161\u00ED protil\u00E1tky. Tato molekula byla vyrobena pro pot\u0159eby onkologie k syst\u00E9mov\u00E9 aplikaci. Proveden\u00E9 studie prok\u00E1zaly jej\u00ED efekt ve smyslu redukce makul\u00E1rn\u00EDho ed\u00E9mu a zlep\u0161en\u00ED zrakov\u00E9 ostrosti u pacient\u016F s DME."@cs . "14110" . "Bevacizumab (Avastin) in treatment of refractory diabetic macular edema"@en . "978-80-254-5927-0" . "67"^^ . "Diabetic macular edema (DME) is a serious complication of diabetic retinopathy (DR) and causes a decrease in visual acuity in affected patients. It occurs primarily in type 2 diabetics. Type 1 diabetes is mainly characterized by proliferative changes that cause the traction and vitreous haemorrhage. DME occurs at any stage of DR, ie non-proliferative and proliferative form and is mainly caused by increased vascular permeability of capillary network in the macular area. It leads to the deposition of lipoproteins and thickening of the retina in the central region. In the initial stages of DME is a reversible decrease in visual acuity. Prolonged edema leads to irreversible loss of visual acuity. Bevacizumab (Avastin - Genet, Roche) is an antibody against VEGF-A molecule. It is a complete humanized mouse antibody molecule. This molecule was constructed for the needs of oncology to systemic application."@en . "Praha" . . "Praha" . . . "Kol\u00E1\u0159, Petr" . . "Bevacizumab (Avastin) v l\u00E9\u010Db\u011B refraktern\u00EDho diabetick\u00E9ho makul\u00E1rn\u00EDho ed\u00E9mu"@cs . "N" . "Bevacizumab (Avastin) v l\u00E9\u010Db\u011B refraktern\u00EDho diabetick\u00E9ho makul\u00E1rn\u00EDho ed\u00E9mu"@cs . "2009-11-27+01:00"^^ . "RIV/00216224:14110/09:00044547!RIV11-MSM-14110___" . "304943" . "RIV/00216224:14110/09:00044547" . . "diabetic macular edema; bevacizumab"@en . . "Bevacizumab (Avastin) v l\u00E9\u010Db\u011B refraktern\u00EDho diabetick\u00E9ho makul\u00E1rn\u00EDho ed\u00E9mu" .